NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
After market 08:00:00 pm | |||
| 140.9 USD | -0.37% |
|
141.1 | +0.15% |
| Jul. 16 | Novo Nordisk's Main Owner Leads $100 Million Financing of Biotech Firm Asceneuron | DJ |
| Jul. 16 | Novo owner backs Swiss biotech Asceneuron in $100 million round | RE |
ETFs positioned on Novo Nordisk A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.75% | 9 M€ | -4.31% | - |
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
956.8
DKK
Spread / Average Target
-1.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +61.53% | 856B | |
| -3.66% | 359B | |
| +15.06% | 325B | |
| +9.18% | 297B | |
| +5.89% | 234B | |
| +16.53% | 226B | |
| +15.67% | 177B | |
| +2.47% | 165B | |
| +2.41% | 126B |
- Stock Market
- Equities
- NOVO B Stock
- NVO Stock
- ETFs Novo Nordisk A/S
